0d373d8e-2507-4d88-8e19-d3f7b66955b4
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 74
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TGF_BETA_SIGNALING+0.220
- HEDGEHOG_SIGNALING+0.210
- MYC_TARGETS_V2+0.200
- WNT_BETA_CATENIN_SIGNALING+0.170
- UNFOLDED_PROTEIN_RESPONSE+0.130
- NOTCH_SIGNALING+0.120
- UV_RESPONSE_DN+0.110
- MYOGENESIS+0.090
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.080
- ANGIOGENESIS+0.070
Top 10 suppressed
- INTERFERON_GAMMA_RESPONSE-0.410
- E2F_TARGETS-0.380
- INTERFERON_ALPHA_RESPONSE-0.380
- ALLOGRAFT_REJECTION-0.340
- MTORC1_SIGNALING-0.330
- IL6_JAK_STAT3_SIGNALING-0.320
- G2M_CHECKPOINT-0.280
- INFLAMMATORY_RESPONSE-0.270
- CHOLESTEROL_HOMEOSTASIS-0.260
- FATTY_ACID_METABOLISM-0.260
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | ERR2208931 | — | — | 0.831 |
| 2 | TCGA-A1-A0SB-01A-11R-A144-07 | — | A | 0.797 |
| 3 | TCGA-OR-A5J9-01 | Adrenocortical Carcinoma | Adrenocortical Carcinoma, Usual Type | 0.796 |
| 4 | MBCProject_0832_T1_RNA | — | A | 0.790 |
| 5 | GSM5359429 | — | — | 0.789 |
| 6 | AUR-AD9E-TTM2-A-1-1-R-A542-39 | — | B | 0.785 |
| 7 | SRR8518202 | — | A | 0.783 |
| 8 | TCGA-D8-A1XB-01A-11R-A14D-07 | — | A | 0.780 |
| 9 | 38aa467f-bd67-475e-9280-7e710bdc0cb3 | — | — | 0.780 |
| 10 | 20ed86b0-2e3d-44ec-88cd-eac5486fe15c | — | — | 0.779 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 17 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TGF_BETA_SIGNALING | 0.220 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.210 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.200 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.170 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.130 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.120 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.110 | Inavolisib | — uncovered |
| MYOGENESIS | 0.090 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.080 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.070 | Remibrutinib | — uncovered |
| APICAL_JUNCTION | 0.070 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.070 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.040 | Inavolisib | — uncovered |
| COAGULATION | 0.030 | Binimetinib | — uncovered |
| HYPOXIA | 0.030 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.030 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.010 | Remibrutinib | — uncovered |